Adverum Biotechnologies (ADVM) Earnings Date, Estimates & Call Transcripts $2.63 -0.10 (-3.66%) Closing price 07/15/2025 04:00 PM EasternExtended Trading$2.62 -0.01 (-0.23%) As of 07/15/2025 07:28 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock Adverum Biotechnologies Earnings Summary Adverum Biotechnologies announced Q4 2024 earnings on April 15, 2025, reporting an EPS of -$1.96, which missed analysts' consensus estimates of -$1.34 by $0.62. With a trailing EPS of -$6.40, Adverum Biotechnologies' earnings are expected to decrease next year, from ($4.92) to ($5.20) per share. Upcoming Earnings DateAug. 11Before Market OpensEstimatedConsensus EPS (Apr. 15) -$1.34 Actual EPS (Apr. 15) -$1.96 Missed By -$0.62 Q4 2024 Earnings ResourcesQ4 2024 Earnings Report Annual Report (10-K) Press Release (8-K)ADVM Upcoming EarningsAdverum Biotechnologies' Q2 2025 earnings is scheduled for Monday, August 11, 2025, with a conference call scheduled on Friday, August 8, 2025 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Powered by Get Adverum Biotechnologies Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Adverum Biotechnologies and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataADVM Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.ADVM Estimated and Actual Revenue by QuarterEstimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Adverum Biotechnologies Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ2 20251-$2.25-$2.25-$2.25Q3 20251-$1.19-$1.19-$1.19Q4 20251-$1.17-$1.17-$1.17 Adverum Biotechnologies Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame Start Date End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails 8/11/2025(Estimated)--------4/15/2025Q4 2024-$1.34-$1.96 -$0.62-$1.96--11/4/2024--$1.20-$1.30 -$0.10-$1.30$0.50M$1.00M8/12/2024Q2 2024-$1.47-$0.89+$0.58-$0.89$0.53M-5/9/2024Q1 2024-$1.28-$1.50 -$0.22-$1.50--3/18/2024Q4 2023-$2.80-$2.30+$0.50-$2.30--11/9/2023Q3 2023-$3.00-$3.30 -$0.30-$0.33--8/10/2023Q2 2023-$3.20-$3.10+$0.10-$0.31-- Adverum Biotechnologies Earnings - Frequently Asked Questions When is Adverum Biotechnologies' earnings date? Adverum Biotechnologies has not confirmed its next earnings publication date, but the company's estimated earnings date is Monday, August 11th, 2025 based off last year's report dates. Learn more on ADVM's earnings history. Did Adverum Biotechnologies beat their earnings estimates last quarter? In the previous quarter, Adverum Biotechnologies (NASDAQ:ADVM) missed the analysts' consensus estimate of ($1.34) by $0.62 with a reported earnings per share (EPS) of ($1.96). Learn more on analysts' earnings estimate vs. ADVM's actual earnings. How much revenue does Adverum Biotechnologies generate each year? Adverum Biotechnologies (NASDAQ:ADVM) has a recorded annual revenue of $1 million. How much profit does Adverum Biotechnologies generate each year? Adverum Biotechnologies (NASDAQ:ADVM) has a recorded net income of -$130.93 million. ADVM has generated -$6.40 earnings per share over the last four quarters. What is Adverum Biotechnologies' EPS forecast for next year? Adverum Biotechnologies' earnings are expected to decrease from ($4.92) per share to ($5.20) per share in the next year. More Earnings Resources from MarketBeat Related Companies ProKidney Earnings Date Alumis Earnings Date Eledon Pharmaceuticals Earnings Date Cybin Earnings Date Instil Bio Earnings Date Puma Biotechnology Earnings Date Voyager Therapeutics Earnings Date I-Mab Earnings Date Lifevantage Earnings Date Enanta Pharmaceuticals Earnings Date Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles 3 Analysts Set $600 Target Ahead of Microsoft EarningsTesla: 2 Plays Ahead of Next Week's Earnings ReportFastenal Surges After Earnings Beat, Tariff Risks Loom3 Catalysts Converge on Intel Ahead of a Critical Earnings ReportSmith & Wesson Stock Falls on Earnings Miss, Tariff WoesWhat to Expect From the Q2 Earnings Reporting CycleBroadcom Slides on Solid Earnings, AI Outlook Still Strong This page (NASDAQ:ADVM) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhy Elon is funding the “Quantum Power Grid”Elon knows the future isn’t about smarter AI — it’s about powering it. And this new technology is quietly b...True Market Insiders | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredThis Social Security Shift Could Boost Benefits by 400%If you currently collect Social Security—or plan to in the future—this may be one of the most important update...InvestorPlace | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adverum Biotechnologies, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Adverum Biotechnologies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.